---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055052"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:18:32.577486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review

## Summary
- Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.
- Revumenib NDA for R/R KMT2Ar acute leukemia granted Priority Review; PDUFA date Sep 26, 2024.
- Axatilimab BLA for chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.
- Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected 4Q24, potential sNDA 1H25.
- Appointed Steven Closter as Chief Commercial Officer; R&D expenses rose to $56.5M from $34.1M YoY.

## SEC filing metadata
- accession: 0000950170-24-055052
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/0000950170-24-055052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/sndx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055052
- JSON: https://secwatch.observer/filing/0000950170-24-055052.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055052.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported the quarter ended March 31, 2024 results: net income net loss attributable to common stockholders of $72.4 million, EPS $0.85 per share.
  - Period: the quarter ended March 31, 2024
  - Net income: net loss attributable to common stockholders of $72.4 million
  - EPS: $0.85 per share
  - Result: reported results
  source text: Syndax reported a net loss attributable to common stockholders of $72.4 million, or $0.85 per share, compared to a net loss attributable to common stockholders of $41.1 million, or $0.59 per share, for the comparable prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/0000950170-24-055052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.